Abstract 17P
Background
Gastric cancer is a multifaceted condition exhibiting varied responses to treatment, emphasizing the need for tailored therapeutic strategies. This study endeavors to elucidate the cellular interactions and molecular mechanisms that underlie the response to Sintilimab plus SOX (fluorouracil plus oxaliplatin) therapy among gastric cancer patients.
Methods
Single-cell sequencing and multiplex immunohistochemistry (mIHC) were employed to elucidate the spatial characteristics linked to the response of gastric cancer to chemo- and immuno- treatment. By integration of mIHC, feature extraction, and machine learning algorithms, we elucidated the intricate interactions between cellular populations and developed a Support Vector Machine (SVM) model for the prediction of treatment response.
Results
We initially discovered a significant correlation between apical membrane cells and resistance to fluorouracil and oxaliplatin, both crucial components of the treatment regimen. This prompted us to delve into the involvement of apical membrane cells in treatment response. Through a thorough examination of cell interactions, we noted substantial connections between apical membrane cells and resident macrophages. Further analysis of ligand-receptor interactions unveiled specific molecular associations, with TGFB1-HSPB1 and LTF-S100A14 interactions standing out, indicating potential signaling pathways implicated in treatment response. To forecast treatment response, we developed an SVM model integrating six markers (DUOX2, HSPB1, S100A14, C1QA, TGFB1, and LTF), which demonstrated outstanding predictive capacity, achieving high area under the curve (AUC) values of 0.93 in the exploration cohort and 0.84 in the validation cohort.
Conclusions
Our research underscored the importance of integrating multi-omics data alongside spatial information in predictive model, holding the promise of steering personalized therapeutic decisions and enhancing treatment efficacy.
Legal entity responsible for the study
The First Affiliated Hospital, School of Medicine, Zhejiang University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
170P - Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma: a window-of-opportunity trial of nivolumab with BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8)
Presenter: Nicholas Venturini
Session: Poster Display
171P - Immune landscape and CLEVER-1 expression in hepatoblastoma
Presenter: Ville Väyrynen
Session: Poster Display
172P - PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment
Presenter: Ju Yang
Session: Poster Display
173P - Depleting resident peritoneal macrophages is an effective treatment for peritoneal metastasized colorectal cancer
Presenter: Job Saris
Session: Poster Display
174P - Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity
Presenter: Yizhi Zhan
Session: Poster Display
175P - MicroRNA-548c: An Immune-Activator microRNA at the Tumor Microenvironment and Immune Milieu of Breast Cancer
Presenter: Alyaa Dawoud
Session: Poster Display
176P - Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study
Presenter: Andrea Joaquin Garcia
Session: Poster Display
177P - The Immune-microenvironment Confers Chemoresistance in Breast cancer through activation of VEGFR2/STAT3/BIRC5 signaling
Presenter: Bhawna Deswal
Session: Poster Display
178P - Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy / immunotherapy.
Presenter: Charlotte Birchall
Session: Poster Display
179P - Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort
Presenter: Mattia Rediti
Session: Poster Display